H.C. Wainwright analyst Robert Burns raised the firm’s price target on Caribou Biosciences to $24 from $23 and keeps a Buy rating on the shares following the Q4 report. The analyst says dose expansion data for CB-010 is expected imminently.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBU:
- CRBU Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Caribou Biosciences (NASDAQ:CRBU): Recent Price Volatility May Offer Investors an Entry Point
- Caribou should be bought on ‘illogical weakness,’ says Citi
- Caribou Biosciences reports Q4 EPS (39c), consensus (37c)
- Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
